Ephraim Heller

From Wikipedia, the free encyclopedia

Ephraim Heller is an inventor and entrepreneur, and the current CEO of SynAgile Corporation.[1] SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went[2] public and was later sold to Abbott Labs for $1.2 billion.[3] He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a venture partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard. His father is the engineer Adam Heller.

Patents[]

Ephraim Heller holds over 100 US patents, including patents on blood glucose monitors and photocatalytic materials.[4]

References[]

  1. ^ http://www.synagilepharma.com
  2. ^ "THERASENSE INC, Form S-1, Filing Date Oct 11, 2000" (PDF). secdatabase.com. Retrieved May 15, 2018.
  3. ^ "THE MARKETS: STOCKS & BONDS; Corporate Earnings Jitters Send Shares Modestly Lower". The New York Times. 14 January 2004.
  4. ^ http://search.usa.gov/search?affiliate=web-sdmg-uspto.gov&commit=Search&embedded=&filter=moderate&locale=en&m=&page=2&query=%22heller%2C+ephraim%22&sc=0&utf8=✓

External links[]

  • Profile in Businessweek
  • Abbott Labs: "In April 2004, Abbott announced it had completed the acquisition of TheraSense, a leader in developing blood glucose self-monitoring devices that require very small blood samples to deliver rapid test results".
  • Abbott's Annual Report for Fiscal Year 2003 featured the acquisition of Therasense on its cover.
  • New York Times, January 14, 2004: "A deal by Abbott Laboratories to buy TheraSense for $1.2 billion in cash to bolster its diabetes drugs sent TheraSense up 31 percent , gaining $6.34, to $26.64. Abbott rose 24 cents, to $44.43."
Retrieved from ""